Compare Redwire Corporation (RDW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Tango Therapeutics Inc. — how do they compare? Redwire Corporation trades at $8.32 (market cap $2.29B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Redwire Corporation for 18 Days and Tango Therapeutics Inc. for 0 Days on average.
| RDW | TNGX | |
|---|---|---|
Market Cap | $2.29B | $3.75B |
Volume | 9,800,070 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $25.90 | $32.90 |
52-Week Low | $5.06 | $7.50 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $1.82B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire Corporation (RDW) trades at $9.16, down 0.65% on the day, showing bearish technical signals despite recent contract wins. The company reported strong revenue growth with Q2 2026 showing 89.6% year-over-year increase, but continues to post significant losses with a net income margin of -57.26%. Recent developments include a $981 million Space Force contract award and partnerships with Honda and Sophia Space for orbital infrastructure projects.
While analyst consensus remains bullish with an 80% buy rating and $14.88 price target, the stock faces substantial execution risks amid persistent losses and negative cash flow from operations. The company's growth trajectory depends heavily on successful contract execution and SpaceX's Starship development, making this a high-risk, high-potential investment in the emerging space economy.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
